Webinars & Videos from Sino Biological

The information and opinions provided by speakers as well as Sino Biological employees during hosted webinar series are solely of their own and Sino Biological assumes no responsibility or liability for this content.

Webinars

Hosted by Sino BiologicalMarch 25, 2021, 2PM, ESTSAXS-enabled Studies of mAbs Improve Detection of SARS-CoV-2 Nucleocapsid Protein & Reveal Conformational Plasticity-dependent Potency Changes

	Michal Hammel, Ph.D.

	• Research Scientist at Lawrence Berkeley National Laboratory • Founder of SAXS Consulting, Inc

	Curtis D. Hodge, Ph.D.

	• Postdoctoral Fellow at Lawrence Berkeley National Laboratory • Co-Founder & CEO of Nanotein Technologies, Inc.

Watch Video Watch Video

Hosted by Sino BiologicalFebruary 26, 2021, 2PM, ESTCharacterization and Selection of Antibodies for COVID-19 Diagnostics Using Surface Plasmon Resonance (SPR)

	Michael Piazza, Ph.D.

	Systems Integration Manager, Nicoya

	Soleil Grisé

	Senior Product Manager, Nicoya

	Rob Burgess, Ph.D.

	Chief Business Officer, Sino Biological

Watch Video Watch Video

You'll Learn About

	Versatility & Flexibility: How the robustness and sensitivity of SPR makes it ideal for a wide range of biomolecular applications
	Comprehensive Workflows: The benefits of SPR-based characterization studies for accelerating lead time on novel COVID-19 solutions
	Maximizing Performance: How to develop a highly selective and specific antibody pair with SPR to optimize COVID-19 antigen detection
	Looking Ahead: The next generation of SPR platforms advancing label-free detection to address the unmet needs of infectious disease research

Cell Press Webinar | Sponsored by Sino BiologicalAugust 4, 2020 12 PM ETTherapies and Vaccine Development for Emerging and Re-emerging Diseases

Efficacy of SARS-CoV-2 Vaccines in Pre-clinical Models
	Mike Diamond
	The Herbert S. Gasser Professor/ Associate Director Departments of Medicine, Molecular Microbiology, Pathology & Immunology, Washington University School of Medicine, St. Louis/ Center for Human Immunology and Immunotherapy Programs

Rapid COVID-19 Vaccine Development Enabled by Prototype Pathogen Preparedness
	Barney Graham
	Deputy Director, Vaccine Research Center/ Chief, Viral Pathogenesis Laboratory National Institute of Allergy and Infectious Diseases (NIAID/NIH)

Preparedness for Emerging and Re-emerging Diseases-Lessons from mAb114 (Ebola)
	Nancy Sullivan
	Chief, Biodefense Research Section VCR/NIAID/NIH

Watch Video Watch Video

Abstract:
The emergence of the SARS-CoV-2/COVID-19 pandemic has exposed our continued susceptibility to microbial pathogens and gaps in our therapeutic arsenal. In this webinar, the speakers illustrated the concept of bench-to-bedside research by collectively laying out the avenues necessary for vaccines/therapeutics to progress from pre-clinical work to patients.

August 18, 2020Bioactivity Evaluation of Neutralizing Antibodies In Vitro

August 27, 2020 7 AM PT Atlas of the SARS-CoV-2 Proteome

August 14, 2020 11 AM ET A Ticking Time Bomb: Tracing the Origin and Spread of SARS-CoV-2

A Historical Overview of Coronavirus Spillovers from Animals to Humans
	Linda J. Saif, Ph.D.
	Distinguished University Professor Food Animal Health Research Program and the College of Veterinary Medicine Co-Director Virus and Emerging Pathogens Program, Infectious Disease Institute OARDC/The Ohio State University

The Spike D614G Mutation Increases SARS-CoV-2 Infection of Multiple Human Cell Types
	Neville Sanjana, Ph.D.
	Core Faculty Member, New York Genome Center Assistant Professor of Biology, New York University Assistant Professor of Neuroscience and Physiology, NYU School of Medicine

Watch Video Watch Video

Abstract:
Due to the COVID-19 pandemic, research on the origins and spread of coronaviruses is taking center stage. In this The Scientist webinar sponsored by Sino Biological, coronavirus experts described how SARS-CoV-2 came to infect humans. Linda Saif gave a historical overview of SARS spillovers from animals to humans, and Neville Sanjana described recent work on a SARS-CoV-2 spike protein variant that increases human infectivity.

July 28, 2020 2:30 PM ETPutting the Brakes on SARS-CoV-2: Neutralizing Antibodies

Human Monoclonal Antibodies for SARS-CoV-2
	James E. Crowe, Jr., MD
	Director, Vanderbilt Vaccine Center Professor, Pediatrics and Pathology, Microbiology and Immunology Ann Scott Carrell Chair

SARS-CoV-2 Neutralizing Antibodies for Global Access
	Devin Sok, Ph.D.
	Senior Director, Antibody Discovery and Development IAVI

Watch Video Watch Video

Abstract:
To control the global COVID-19 pandemic, researchers are exploring various medical interventions, including neutralizing monoclonal antibodies (mAbs). The SARS-CoV-2 spike (S) glycoprotein, which promotes entry into host cells, is the main target of neutralizing antibodies. In this The Scientist webinar sponsored by Sino Biological, a panel of researchers discussed potential neutralizing antibodies currently under investigation for SARS-CoV-2 treatment.

June 17, 2020 2:30 PM ETComprehending a Pandemic: SARS-CoV-2 Uncovered

The Basic Biology of SARS-CoV-2 and Its Potential Host-pathogen Interactions
	Emily Troemel, Ph.D.
	Professor, Cell and Developmental Biology Division of Biological Sciences University of California San Diego

The Current State of the Field in SARS-CoV-2 Molecular Biology Research
	David Wang, Ph.D.
	Professor, Departments of Molecular Microbiology and Pathology & Immunology Washington University School of Medicine in St Louis

Watch Video Watch Video

Abstract:
SARS-CoV-2, the coronavirus behind the COVID-19 pandemic, has infected hundreds of thousands of people. In response, the scientific community sprang into action to uncover its sequence, structure, and potential biological mechanisms. This information helps guide public health policies as well as drug, vaccine, and diagnostic test development. In this The Scientist webinar sponsored by Sino Biological, speakers discussed the emergence of SARS-CoV-2, diagnostic tests and possibilities for treatment.

Novel COVID-19 Immunodiagnostic Webinar Series Hosted by Sino Biological

Sino Biological's Novel COVID-19 Immunodiagnostic webinar series provides a platform where new technologies can be shared among research and industrial leaders. The invited speakers are industrial and academic scientists working on a variety of novel diagnostic assays. The scope of the webinars includes assays that:
1. detect the virus itself, or viral antigens, with high specificity and sensitivity
2. can allow high-throughput testing
3. can simultaneously detect multiple antigens and/or antibodies
4. use different detection systems than colloidal gold

Watch On-demand

July 21, 2020 | 2 p.m. ESTAdarza BiosystemsAnalyzing the Human Antibody Response to Pandemic Respiratory Viruses with Adarza's New ZIVA™ Platform and High Definition Antigen Arrays: A Case Study on COVID-19

	Benjamin Miller, Ph.D.

	Founder, Adarza Biosystems Dean's Professor of Dermatology, Biochemistry and Biophysics, Biomedical Engineering, and Optics, University of Rochester

Watch Video Watch Video

Abstract:
Detection of antibodies to upper respiratory pathogens is critical to surveillance, assessment of the immune status of individuals, vaccine development, and basic biology. The urgent need for antibody detection tools has proven particularly acute in the COVID-19 era. While most clinical diagnostics have focused on detection of antibodies to single antigens, array-based tools are desirable as methods for assessing broader patterns of antigen-specific responses, as well as providing information on SARS-CoV-2 immunity in the context of pre-existing immunity to other viruses. To that end, this talk will describe a multiplex label-free antigen microarray on the Arrayed Imaging Reflectometry (AIR) platform for detection of antibodies to SARS-CoV-2, SARS-CoV-1, MERS, three circulating coronavirus strains (HKU1, 229E, OC43) and three strains of influenza. As a label-free technology, AIR as implemented on the ZIVA™ platform provides rapid sample analysis via a simple, "one-step" workflow. The array is readily able to distinguish uninfected from convalescent COVID-19 subjects, and provides quantitative information about total Ig, as well as IgG- and IgM-specific responses.

July 23, 2020 | 2 p.m. ESTQuanterix | Institut PasteurCytokine Biomarkers of Inflammatory Response in COVID-19 Patients

	Kevin Hrusovsky

	President, Chairman and CEO Quanterix

	Dan Sikkema, Ph.D.

	Vice President, Accelerator and Pharma Services Quanterix

	Darragh Duffy, Ph.D.

	Scientific Manager LabEx Milieu Interieur, Institut Pasteur

Watch Video Watch Video

Abstract:
Ultrasensitive SIMOA™ Immunoassays Impacting COVID-19, Infectious Diseases, and Immunology
As COVID-19 pandemic preparedness initiatives ramp up to address the current crisis, one area of focus has been the improvement of testing methods to re-open society. Differentiating early symptoms from other respiratory pathogens that have a similar clinical presentation, identifying those patients at risk for severe symptoms such as "cytokine storm," and determining immunity status have been hallmarks of scientific efforts over the past several months. The Quanterix SIMOA™ platform is an ultra-sensitive immunoassay system that is typically 100-1000-fold more sensitive than most ELISA systems. This level of sensitivity offers the ability to detect and quantitate key cytokines involved early in the disease progression and provides insight like "a radar system" into "prediction" of subsequent immune complications. Here we describe efforts around frontline immunological and serologic assessments of COVID-19 patients and examples of historical approaches for auto-immune, vaccine, and infectious disease research using SIMOA technology.

Impaired Type I Interferon Activity and Exacerbated Inflammatory Responses in Severe Covid-19 Patients
Coronavirus disease 2019 (Covid-19) is characterized by distinct patterns of disease progression implying diverse host immune responses. We performed an integrated immune analysis on a cohort of fifty Covid19 patients with various disease severity. A unique phenotype in severe and critical patients was identified. It consisted of a profoundly impaired interferon (IFN) type I response characterized by no IFN-b and low IFN-a production and activity, associated with a persistent blood virus load and exacerbated inflammatory response. The cytokine storm was partially driven by the transcriptional factor NFkB and characterized by increased tumor necrosis factor (TNF)- a and interleukin (IL)-6 production and signaling. We propose that type-I IFN def.

July 28, 2020 | 2 p.m. ESTGyros Protein TechnologiesMicrofluidic, Nanoliter-scale Immunoassays for Rapid SARS-CoV-2 Antibody Analysis in Serology Testing, and Vaccine and Biotherapeutics Development

July 30, 2020 | 2 p.m. ESTUniversity of MichiganRapid and Quantitative Detection of SARS-CoV-2 Specific IgG for Convalescent Plasma Therapy

	Xiaotian Tan, Ph.D.

	Research Fellow University of Michigan

Watch Video Watch Video

Abstract:
COVID-19 pandemic has caused more than a half-million of deaths and is now a severe threat to global health. Clinical practice has demonstrated that the SARS-CoV-2 S1 specific antibodies (especially IgG) can be used as a prognostic marker of COVID-19. More importantly, neutralization IgG is the major effective ingredient in convalescent plasma therapy. Thus, knowing the concentration of SARS-CoV-2 S1-specific IgGis important for selecting appropriate convalescent plasma donors. However, the popular point-of-care biomarker detection technologies, such as the lateral-flow test strips, provide only yes/no information and have very limited sensitivities. Thus, it cannot be used for the quantitative evaluation of the therapeutic efficacy of the recovered patient's plasma/serum. Conventional ELISA (enzyme-linked immunosorbent assay), on the other hand, can provide quantitative, accurate, and sensitive results, but it involves complicated and expensive instruments and long assay time. In addition, samples need to be sent to centralized labs, which significantly increases the turn-around time. Here, we present a microfluidic ELISA technology for rapid (<15 min), quantitative, sensitive detection of SARS-CoV-2 S1 specific IgG in human serum. We also characterized various humanized monoclonal IgG and identified a candidate, D006, which has a high binding affinity and a relatively high specificity towards SARS-CoV-2 S1 protein that can serve as the calibration standard of anti-SARS-CoV-2 S1 IgG in serological analyses. With the aforementioned technology, we demonstrated that we were able to identify the best donor candidate for the convalescent plasma therapy, with a tiny drop of blood sample (<8 µL) and a fixed dilution factor (200 X). In addition, we also demonstrated that our microfluidic ELISA technology can sensitively detect SARS-CoV-2 antigens (S1 and N proteins) with LLODs at ~10 pg/mL in <40 minutes. Therefore, our technology will greatly facilitate rapid and quantitative analysis of COVID-19 related markers for both therapeutic and diagnostic purposes.

August 4, 2020 | 2 p.m. ESTE25BioFrequency of Direct Antigen Rapid Testing for COVID-19 Reduces Transmission

August 6, 2020 | 2 p.m. ESTNirmidas Biotech | Stanford UniversityHigh-Accuracy Multiplexed SARS-CoV-2 Antibody Assay with Avidity and Saliva Capability on a Nano-Plasmonic Platform

	Meijie Tang, Ph.D.

	CEO Nirmidas Biotech Inc.

	Hongjie Dai, Ph.D.
	Professor Department of Chemistry and Bio-X, Stanford University

Watch Video Watch Video

Abstract:
The outbreak and rapid spread of SARS-CoV-2 virus has led to a dire global pandemic with millions of people infected and ~ 400,000 deaths thus far. Highly accurate detection of antibodies for COVID-19 is an indispensable part of the effort to combat the pandemic. In this talk I will present two-plex antibody detection against SARS-CoV-2 spike proteins (the S1 subunit and receptor binding domain RBD) in human serum and saliva on a near-infrared nano-plasmonic gold (pGOLD) platform. By testing nearly 600 serum samples, pGOLD COVID-19 assay achieved ~ 99.78 % specificity for detecting both IgG and IgM with 100 % sensitivity in sera collected > 14 days post disease symptom onset, with zero cross-reactivity to other diseases. Two-plex correlation analysis revealed higher binding of serum IgM to RBD than to S1. IgG antibody avidity toward multiple antigens were measured, shedding light on antibody maturation in COVID-19 patients and affording a powerful tool for differentiating recent from remote infections and identifying re-infection by SARS-CoV-2. Just as important, due to high analytical sensitivity, the pGOLD COVID-19 assay detected minute amounts of antibodies in human saliva, offering the first non-invasive detection of SARS-CoV-2 antibodies. If time permits, this talk will also briefly present a rapid test of IgG/IgM assay for SARS-CoV-2 developed by the Nirmidas Team.

August 13, 2020 | 2 p.m. ESTGator BioNext Generation BLI: Novel Applications in the Fight against COVID-19

	Hong Tan, Ph.D.

	CEO Gator Bio

	Indrani Chakraborty

	Application Scientist Gator Bio

Watch Video Watch Video

Abstract:
Biolayer Interferometry (BLI) is widely accepted in the biopharmaceutical industry for quantitation and kinetics analysis of biomolecules. Gator Bio, a company started by the founder of ForteBio and the inventors of Octet, has created the next generation of BLI technology. This presentation will introduce the Gator instruments and associated biosensing probes, and highlight how Gator can help scientists research SARS-CoV-2 virus and develop COVID-19 drugs and vaccines. Several application examples will be presented to demonstrate Gator's capability to generate high-quality, information-rich datasets.

SARS-CoV-2 Webinar Series Sponsored by Sino Biological

1pm EST, June 30, 2020 Engineering Optimized Anti-SARS-CoV-2 Antibody Therapeutics

Functional Assays to Test Potency of Anti-SARS-CoV-2 Neutralizing Antibodies
	Sawsan Youssef
	CSO

	Distributed Bio, Inc.

Dissecting the SARS-CoV-2 Proteome
	Yuning Chen, Ph.D.
	R&D Manager

	Sino Biological Inc.

The Role of Biosensing in Anti-SARS-CoV-2 Therapeutic Discovery
	Sindy Liao Chan
	Director, Biosensor/High Throughput Protein Interactions
	Distributed Bio, Inc.

RBD Engineering and Antibody Discovery by Yeast Display
	Jack Wang
	Senior Scientist

	Distributed Bio, Inc.

Combinatorial Engineering of Anti-SARS Antibodies to Recognize COVID-19 RBD, Using Tumbler
	Shahrad Daraeikia
	Senior Scientist

	Distributed Bio, Inc.

Watch Video Watch Video

1pm EST, May 27, 2020Multiplex Serological Assays for COVID-19

Application of SARS-CoV-2 Serological Assays for Monitoring the Epidemic and Qualification of Donors and Plasma for Use as COVID-19 Convalescent Plasma (CCP)
	Michael P. Busch, MD, Ph.D.

	Director, Vitalant Research Institute; Senior Vice President for Research and Scientific Programs, Vitalant; Professor of Laboratory Medicine, University of California, San Francisco

Optimized Development of Pathogen Inactivated COVID-19 Convalescent Plasma
	Laurence M. Corash, MD
	Co-Founder & CSO

	Cerus

Analysis of SARS-CoV-2 Antibodies in COVID-19 Convalescent Plasma Using a Coronavirus Antigen Microarray
	Philip Felgner, Ph.D.
	Director
	Protein Microarray Laboratory, Infectious Diseases, School of Medicine, University of California, Irvine

Watch Video Watch Video

2:30pm, May 21, 2020SARS-CoV-2 (COVID-19) Vaccine Development

A Global Health Vaccine for COVID-19
	Peter Hotez, MD, Ph.D.

	National School of Tropical Medicine; Professor, Departments of Pediatrics, Molecular Virology & Microbiology; Co-Head, Section of Pediatric Tropical Medicine; Health Policy Scholar, Baylor College of Medicine

Strategies and Challenges for COVID-19 Antibody Development
	Jiahui Yang, Ph.D.
	Director, R&D

	Sino Biological Inc.

Development of a Single Dose Vaccine Against COVID-19 Using GV-MVA-VLP Vector Platform
	Farshad Guirakhoo, Ph.D.
	CSO

	GeoVax

Watch Video Watch Video

The 4th presentation of the WVC Covid-19 Webinar Series was sponsored by Sino Biological. This webinar was moderated by Dr. Philip Krause, Deputy Director, OVRR, CBER, FDA.
Speaker: Dr. Kate Broderick, SVP R&D Preclinical, Inovio
Subject: Advantages of DNA vaccines in response to COVID-19 and Inovio's progress
Time: 11am, May 12th, 2020

Watch Video

The COVID-19 pandemic has a significant impact on nearly every aspect of ordinary life worldwide. There is an urgent need to establish tool sets to facilitate the generation of therapeutic agents as well as vaccines. In this webinar, Sino Biological focused on the design, strategy, process, and troubleshooting in generating high-quality viral proteins via recombinant protein expression technologies as well as the multi-strategic effort for generating anti-viral antibodies for serological diagnostic applications.

Watch Video

Technical Resource

In this complimentary guide, specific case studies will be conducted on the problems encountered in the development of recombinant proteins in several common expression systems, including expression host choice, vectors, expression fragments, culture condition and purification, etc.

Download the guide to learn:
1. Recombinant Protein Expression Overview
2. Key Influencing Factors for Protein Expression
3. FAQs & Case Studies

Download Download

In this guide, you can learn the technical information about antibody development, from immunization, technology platform selection, antibody screening to quality validation, and an in-depth overview of featured technology platforms for monoclonal antibody development, including traditional hybridoma technology and phage display based on recombinant method.

Download the free guide to learn:
1. Antibody Development Introduction
2. Antibody Application Validation
3. How to Choose a Proper Antibody Reagent

Download Download

FREE guide about all details of mAb generation platforms shared by Sino Biological.

Download this FREE Guide to Learn:
Principles, Processes, Case Studies, and Pros & Cons of the Following MAb Generation Platforms:
Hybridoma Technology
Immunized Phage Display Antibody Library
Human Naïve Antibody Library
Single B Cell Antibody Technology

Download Download

This guide covers general principles and all the key points about how to optimize a FCM experiment, from experimental design, sample preparation, fluorescence staining, detection to data analysis.

Download this FREE Guide to Learn:
• Introduction to Flow Cytometry
• Principle of Flow Cytometer
• Tips & Tricks for Flow Cytometry
• Flow Cytometry Troubleshooting
• Applications in Cancer Research

Download Download

Videos

Sino Biological take a part in Coronavirus Virtual Event on 2nd Apr,2020. We have shared a lot with customers about Sino Biological's effort on Serological Study of COVID-19.

Watch Video

Interview video of Sino Biological made by PEGS Conference.

Watch Video

By Molecule Initial

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Special

Citation Search

	This webinar discusses the approaches used to screen for SARS-CoV-2 (2019-nCoV) neutralizing antibodies and evaluate their bioactivity in vitro.
	Speaker: Dong Li, Ph.D.
	Senior Scientist
	Sino Biological, Inc.
	Watch Video Watch VideoAugust 18-TN

Webinars & Technical Resource & Videos

Webinars

Novel COVID-19 Immunodiagnostic Webinar Series Hosted by Sino Biological

SARS-CoV-2 Webinar Series Sponsored by Sino Biological

Technical Resource

Videos

Featured Products & Service

By Molecule Initial

	Rob Durham, Ph.D.

	Director of Service and Scientific Support Gyros Protein Technologies

	Bobby Brooke Herrera, Ph.D.

	Co-founder & Interim CEO, CSO, E25Bio, Inc. Visiting Scientist, Harvard T.H. Chan School of Public Health